WS02.04 Triple HEMT in Pregnancy and Lactation: effects on the developing lung, gut and pancreas

Abstract

Introduction/aim: The development of new cystic fibrosis (CF) drugs, including the highly effective modulator therapies (HEMT) such as elexacaftor-tezacaftor-ivacaftor (ETI), has enabled more women with CF to reach child-bearing age. However, safety of ongoing use of ETI during pregnancy and breastfeeding, especially for the baby’s developing organs, is unknown. We aim to investigate placental and milk transfer of maternally administered ETI in pre- and postnatal wildtype and F508del-CFTR rats and their bioaccumulation into the developing lungs, gut and pancreas.